Autologous dendritic cell immunotherapy - DiaVacs

Drug Profile

Autologous dendritic cell immunotherapy - DiaVacs

Alternative Names: Dendritic cell-based diabetes therapy - DiaVacs; DV-100; DV-200; DV0100; iDC

Latest Information Update: 11 Dec 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator DiaVacs
  • Class Antihyperglycaemics; Antisense DNA; Dendritic cell vaccines
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Type 1 diabetes mellitus
  • New Molecular Entity No

Highest Development Phases

  • Phase II Type 1 diabetes mellitus

Most Recent Events

  • 11 Dec 2015 Preclinical trials in Type-1 diabetes mellitus in USA (SC)
  • 06 Jan 2014 Phase-II clinical trials in Type-1 diabetes mellitus in USA (Intradermal)
  • 06 Jan 2014 DV 0100 receives Orphan Drug status for Type-1 diabetes mellitus in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top